SO
RAPP

STRS Ohio’s Rapport Therapeutics RAPP Stock Holding History

STRS Ohio’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$108K Buy
2,600
+500
+24% +$18.4K ﹤0.01% 1849
2026
Q1 		$65.7K Hold
2,100
– – ﹤0.01% 1881
2025
Q4 		$63.7K Hold
2,100
– – ﹤0.01% 1923
2025
Q3 		$62.4K Buy
2,100
+400
+24% +$7.13K ﹤0.01% 1960
2025
Q2 		$19.3K Hold
1,700
– – ﹤0.01% 2137
2025
Q1 		$17.1K Hold
1,700
– – ﹤0.01% 1858
2024
Q4 		$30.2K Hold
1,700
– – ﹤0.01% 1782
2024
Q3 		$34.8K Buy
+1,700
New +$36.5K ﹤0.01% 1845

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $498M AUM 267.53% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

STRS Ohio's RAPP Position: Q2 2026 in Review

STRS Ohio increased its Rapport Therapeutics (RAPP) stake by 24% in Q2 2026, buying an estimated $18.4K and bringing the position to 2,600 shares worth $108K. The position accounts for ﹤0.01% of the portfolio, ranked #1849.

STRS Ohio first reported a position in RAPP in Q3 2024 and has held it in 8 quarters since. 161 funds tracked by Wall St. Rank hold RAPP as of Q2 2026.

  • STRS Ohio held 2,600 shares of Rapport Therapeutics worth $108K as of Q2 2026.
  • STRS Ohio bought 500 Rapport Therapeutics shares in Q2 2026, an estimated $18.4K.
  • Rapport Therapeutics made up ﹤0.01% of STRS Ohio's portfolio in Q2 2026, its #1849 holding.
  • STRS Ohio first reported a position in Rapport Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • 161 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q2 2026.

Based on STRS Ohio's 13F filing for Q2 2026, filed 30 Jul 2026.